Jupiter, FL – [May 5th, 2024] – Myosin Therapeutics is proud to announce that Dr. Courtney Miller, CEO and Chair of the Board of Directors, will speak at the BIO International Convention in “Breaking the Cycle: Innovations in Addressing Substance Use Disorder.” The session will bring together leading experts in the field to discuss groundbreaking technologies and interventional programs aimed at tackling substance use disorder (SUD), a tremendous medical and societal challenge.
SUD continues to impose significant strains on individuals, families, and the healthcare system. Within the past year, nearly 60 million individuals have either used illegal drugs or misused prescription medications, with more than 13% of Americans aged 12 and up engaging in drug use monthly. This alarming trend underscores the urgency for new approaches to reduce substance use and provide effective treatment options.
The session will explore the latest NIH-funded biopharma initiatives and patient advocate-led interventional programs that are redefining the landscape of SUD treatment. Innovations such as first-in-class pharmacotherapies are offering fresh perspectives on enhancing clinical intervention and uncovering novel biological pathways to combat substance use. This discussion aims to highlight the strides being made in creating safer and more effective medications to address the SUD epidemic.
Dr. Miller will share insights from Myosin Therapeutics’ pioneering work on MT-110, a first-in-class molecular drug designed to reduce methamphetamine use. MT-110 is designed to target the underlying neurobiological mechanisms of methamphetamine use disorder (MUD), offering a novel approach to disrupting the cycle of substance use. Myosin Therapeutics is preparing to initiate a Phase 1 clinical trial for MT-110 in Q1 2025, marking a critical step towards providing an effective pharmacotherapy for MUD, a disorder for which there are currently no FDA-approved medications.
“I’m looking forward to contributing to this session. Unfortunately, the pipeline for stimulant use disorder therapeutics is incredibly thin, so it’s important we have this vital discussion about patient needs and innovations on the horizon,” said Dr. Courtney Miller. “At Myosin Therapeutics, we are committed to advancing MT-110 as a new hope for those struggling with MUD. Our upcoming Phase 1 trial will be a crucial milestone in our mission to bring this much-needed treatment to patients.”
This 2024 BIO International Convention session will feature cutting-edge companies, the NIH, and patient advocates dedicated to disrupting the field of SUD treatment. Attendees of Dr. Miller’s session can expect a comprehensive overview of the latest advancements and collaborations aiming to end the devastating epidemic of substance use disorder.
About Myosin Therapeutics
Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of the Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for oncology and central nervous system indications with a platform for targeting molecular nanomotor proteins. Myosin’s lead programs for glioblastoma and stimulant use disorder target non-muscle myosin II motor proteins.
About BIO
The Biotechnology Innovation Organization (BIO) is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the globe. BIO provides advocacy, business development opportunities, and a forum for companies to share their research and innovations. The annual BIO Symposium is a premier event that brings together industry leaders, investors, policymakers, and patient advocates to discuss the latest advancements in biotechnology and foster collaborations that drive innovation in healthcare, agriculture, industrial, and environmental sectors.
For more information, email contact@myosintherapeutics.com
